Literature DB >> 12943894

Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure.

Alan H B Wu1, Andrew Smith, Stacey Wieczorek, Jeffrey F Mather, Bret Duncan, C Michael White, Carol McGill, Deb Katten, Gary Heller.   

Abstract

Given the limitations of low enrollments, this study suggests that a change of 130% for B-type natiuretic peptide (BNP) and 90% for N-terminal (NT)-proBNP are necessary before results of serially collected data can be considered statistically different. This study also shows that there are important differences in the performance of BNP versus NT-proBNP in monitoring patients with congestive heart failure that need to be further explored.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12943894     DOI: 10.1016/s0002-9149(03)00741-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  48 in total

1.  Elevated B-type natriuretic peptide level as a marker of subsequent thromboembolic events in patients with atrial fibrillation.

Authors:  Tsuneaki Sadanaga; Shun Kohsaka; Hideo Mitamura; Satoshi Ogawa
Journal:  Heart Vessels       Date:  2010-12-25       Impact factor: 2.037

2.  Variability of NT-proBNP levels in heart failure: implications for clinical application.

Authors:  A Mark Richards
Journal:  Heart       Date:  2007-08       Impact factor: 5.994

3.  National Academy of Clinical Biochemistry (NACB) laboratory medicine guidelines on the clinical utilization and analytical issues for cardiac biomarker testing in heart failure.

Authors:  John Beilby
Journal:  Clin Biochem Rev       Date:  2008-08

Review 4.  Biological and analytical variation of clinical biomarker testing: implications for biomarker-guided therapy.

Authors:  Alan H B Wu
Journal:  Curr Heart Fail Rep       Date:  2013-12

5.  Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction.

Authors:  Lisa C Costello-Boerrigter; Guido Boerrigter; Margaret M Redfield; Richard J Rodeheffer; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Denise M Heublein; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2006-01-04       Impact factor: 24.094

6.  The future of laboratory medicine: understanding the new pressures.

Authors:  Mauro Panteghini
Journal:  Clin Biochem Rev       Date:  2004

7.  Proceedings of the 10th Asian Pacific Congress of Clinical Biochemistry in conjunction with the Australasian Association of Clinical Biochemists' 42nd Annual Scientific Conference.

Authors: 
Journal:  Clin Biochem Rev       Date:  2004

8.  Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure.

Authors:  Michael R Zile; Stacia M Desantis; Catalin F Baicu; Robert E Stroud; Sheila B Thompson; Catherine D McClure; Shannon M Mehurg; Francis G Spinale
Journal:  Circ Heart Fail       Date:  2011-02-24       Impact factor: 8.790

9.  A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.

Authors:  M Gomberg-Maitland; M L Maitland; R J Barst; L Sugeng; S Coslet; T J Perrino; L Bond; M E Lacouture; S L Archer; M J Ratain
Journal:  Clin Pharmacol Ther       Date:  2009-12-09       Impact factor: 6.875

10.  Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy.

Authors:  Paul W X Foley; Berthold Stegemann; Kelvin Ng; Sud Ramachandran; Anthony Proudler; Michael P Frenneaux; Leong L Ng; Francisco Leyva
Journal:  Eur Heart J       Date:  2009-08-07       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.